Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Uldrick Website

Thomas S. Uldrick, M.D.

Portait Photo of Thomas Uldrick
HIV and AIDS Malignancy Branch
Retroviral Disease Section
Staff Clinician
Center for Cancer Research
National Cancer Institute
Building 10, Room 6N106
Bethesda, MD 20892
Phone:  
301-402-6296
Fax:  
301-480-5955
E-Mail:  
uldrickts@mail.nih.gov

Biography

Dr. Uldrick received his B.A. from the University of California at Berkeley, and his M.D. from the State University of New York, Downstate. He trained in internal medicine, hematology, and medical oncology at Columbia University. At Columbia, he completed an M.S. in biostatistics, with a focus on patient-oriented research, under a scholarship funded by an NIH-sponsored Clinical and Translational Science Award. Through the NIH-sponsored Fogarty program, he collaborated with Kaposi sarcoma (KS) researchers in South Africa on issues related to treatment of advanced KS in resource-limited settings. He has served on the NCI Lymphoma Steering Committee Primary Central Nervous System Lymphoma Working Group and participates on the AIDS Clinical Trials Group Independent Endpoint Review Committee for trials investigating KS therapies in sub-Saharan Africa.

Research

Dr. Uldrick's major research interests are the natural history and management of virally associated malignancies that occur in the setting of HIV/AIDS and other immune disorders. Therapeutic studies focus on novel approaches to the treatment of several viral-associated malignancies using approaches that incorporate cytokine and growth factor manupulation and targeting of reservoirs of gamma-herpesvirus infected lymphoid cells using monoclonal antobodies or virus activated cytotoxic therapy.

Active projects include:

(1) Evaluation of the natural history of KSHV-associated disorders, including Kaposi sarcoma, KSHV-associated multicentric Castleman disease, primary effusion lymphoma, and a novel entity we described, KSHV-associated Inflammatory Cytokine Syndrome (KICS)

(2) Early-phase treatment studies in KSHV-associated malignancies employing immune modulating, anti-angiogenic and virus-activated cytotoxic therapies

(3) Evaluation of radiation-sparing approaches for HIV-associated primary CNS lymphoma, with an emphasis on long-term survival and neurocognitive functioning

(4) Evaluation of human genomic alterations and gut associated lymphoid tissue in patients with anal cancer

Current collaborators include:

Deborah Citrin, Radiation Oncology Branch, NCI
Nancy Hessol, UCSF
Frank Maldarelli, Drug Resistance Program, NCI
Anisa Mosam, University of KwaZulu-Natal, South Africa
Irini Sereti, Laboratory of Immunoregulation, NIAID
Giovanna Tosato, Laboratory of Cellular Oncology, NCI
Denise Whitby, Viral Oncology Section, NCI-Frederick
HIV+ Tumor Molecular Characterization Project, Office of Cancer Genomics, NCI

This page was last updated on 7/10/2014.